Original paper
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
Abstract
Dual EGFR-vascular endothelial growth factor (EGFR-VEGF) pathway inhibition has long been studied as a strategy to enhance anticancer efficacy of EGFR tyrosine kinase inhibitor (TKI).1 In the phase 2 JO25567 study in Japan, bevacizumab plus erlotinib (B+E) prolonged progression-free survival (PFS) compared with erlotinib monotherapy (E) (median = 16.0 versus 9.7 mo).2 The overall survival (OS) was similar in two arms (median = 47.0 versus 47.4...
Paper Details
Title
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
Published Date
Sep 1, 2021
Journal
Volume
16
Issue
9
Pages
1426 - 1428
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History